Azelaic Acid Cream Composition Applications Mechanisms

Published

Table of Contents

Azelaic acid, a naturally occurring dicarboxylic acid with the molecular formula C9H16O4, serves as the cornerstone of Krem Z Kwasem Azelainowym, a dermatologically validated treatment for acne, rosacea, and hyperpigmentation. Beyond its anti-inflammatory and keratolytic properties, this compound distinguishes itself through a dual mechanism targeting both bacterial proliferation and abnormal keratinization, offering a scientifically rigorous alternative to conventional therapies.

The formulation of azelaic acid creams integrates a precise balance of emollients, preservatives, and pH adjusters to optimize stability, absorption, and skin compatibility. Clinical efficacy hinges not only on the active ingredient but also on the synergistic interactions between these supporting components, which collectively enhance therapeutic outcomes while minimizing adverse effects. Understanding these intricacies is essential for both practitioners and patients seeking evidence-based solutions for persistent dermatological challenges.

Krem Z Kwasem Azelainowym

Composition and Active Ingredients of Krem Z Kwasem Azelainowym

Azelaic acid-based creams, such as Krem Z Kwasem Azelainowym, are formulated to target hyperpigmentation, inflammatory acne, and rosacea through a combination of pharmacologically active and dermatologically compatible excipients. The primary therapeutic agent, azelaic acid, operates via dual mechanisms—anti-inflammatory and keratolytic—distinguishing it from conventional acne treatments. This section examines its chemical properties, supporting ingredients, and formulation strategies to ensure efficacy, stability, and skin tolerance.

Chemical Structure and Classification of Azelaic Acid

Azelaic acid (C9H16O4) is a naturally occurring dicarboxylic acid derived from the fungal metabolism of Pityrosporum ovale or synthesized via oleic acid oxidation. Its linear carbon chain (9 atoms) with two terminal carboxyl groups (–COOH) enables lipid solubility and interaction with intracellular targets. Structurally, it resembles other dicarboxylic acids like sebacic acid but exhibits superior anti-inflammatory and antimicrobial profiles due to its shorter chain length and ability to inhibit neutrophil chemotaxis.

Key molecular properties:

  • Solubility: Slightly soluble in water (1 g/100 mL at 25°C) but more soluble in ethanol and propylene glycol, facilitating transdermal penetration.
  • pKa: ~4.5 (first dissociation) and ~5.4 (second dissociation), influencing its ionization state at physiological pH (5.5–6.5), which affects absorption and activity.
  • Stability: Degrades under high temperatures (>100°C) or extreme pH (<3 or >9), necessitating formulation safeguards.
  • Additional Ingredients and Their Functional Roles

    The efficacy and tolerability of azelaic acid creams depend on excipients that enhance stability, modulate pH, and improve skin compatibility. Below is a comparative table of common additives, their concentrations, and dermatological benefits, based on peer-reviewed formulations (e.g., Skin Pharmacol Physiol, 2018; J Drugs Dermatol, 2020).
    Ingredient Name Function Concentration Range Skin Benefit/Effect
    Propylene Glycol Solvent, penetration enhancer 5–15% Improves azelaic acid solubility and stratum corneum hydration; may cause mild irritation in sensitive skin.
    Glycerin Humectant, emollient 2–10% Restores skin barrier function; compatible with azelaic acid’s keratolytic effects.
    Sodium Hydroxide (pH adjuster) Regulates pH to 3.5–4.5 Trace amounts Optimizes azelaic acid ionization for absorption; prevents microbial growth.
    Phenoxyethanol Preservative 0.5–1% Broad-spectrum antimicrobial; FDA/EU-approved for cosmetics.
    Cetearyl Alcohol Emulsifier, thickener 1–5% Stabilizes emulsion; non-comedogenic and skin-protective.
    Allantoin Skin protectant, anti-irritant 0.5–2% Accelerates wound healing; mitigates azelaic acid-induced erythema.
    Xanthan Gum Viscosity modifier 0.1–0.5% Ensures even product distribution; enhances user experience.
    Note: Formulations may exclude parabens (e.g., methylparaben) due to allergenic potential, replacing them with phenoxyethanol or benzyl alcohol. Hypoallergenic versions omit fragrances and lanolin derivatives.

    Identifying Counterfeit or Low-Quality Azelaic Acid Creams

    Counterfeit azelaic acid creams often lack proper labeling or use suboptimal excipients, compromising safety and efficacy. The following procedure outlines key verification steps based on INCI (International Nomenclature of Cosmetic Ingredients) standards and red flags:

    1. Label Analysis for INCI Compliance

  • Verify the presence of "Azelaic Acid" (INCI: Azelaic Acid) as the first active ingredient (typically 10–20% for topical use).
  • Red Flag: Labels listing "azelaic acid" without the INCI name or using vague terms like "natural extracts" may indicate adulteration.
  • 2. Excipient Transparency

  • Authentic products disclose all excipients, including preservatives (e.g., Phenoxyethanol, Potassium Sorbate) and emulsifiers (e.g., Cetearyl Alcohol).
  • Red Flag: Missing preservatives or unlisted synthetic fragrances (Parfum) suggest potential microbial contamination or irritant additives.
  • 3. pH Indication

  • Legitimate creams specify a pH range of 3.5–4.5 (optimal for azelaic acid activity).
  • Red Flag: Absence of pH information or claims of "neutral pH" may indicate improper formulation.
  • 4. Manufacturer Credentials

  • Check for CE marking (Europe) or FDA registration (USA) on packaging. Reputable brands (e.g., SkinCeuticals, La Roche-Posay) provide batch numbers and expiry dates.
  • Red Flag: Generic packaging, no manufacturer address, or expired products signal counterfeits.
  • 5. Sensory Evaluation

  • Authentic azelaic acid creams have a neutral to slightly acidic odor (no strong fragrance). Texture should be smooth and non-greasy.
  • Red Flag: Overpowering scent or gritty texture may indicate filler ingredients (e.g., talc, silica).
  • Mechanism of Action: Azelaic Acid vs. Conventional Acne Treatments

    Azelaic acid’s dual mechanism—anti-inflammatory and keratolytic—distinguishes it from benzoyl peroxide (oxidative) and retinoids (comedolytic). Below is a comparative analysis of molecular pathways, supported by clinical studies:
    Azelaic acid inhibits neutrophil chemotaxis by reducing leukocyte adhesion molecule expression (ICAM-1, LFA-1) via NF-κB pathway suppression (Thiboutot et al., 2003). Its keratolytic effects stem from tyrosinase inhibition (IC50 = 0.1 mM), reducing melanin synthesis, and DNA polymerase inhibition in Propionibacterium acnes (MIC = 0.125–0.5% w/v), unlike benzoyl peroxide, which relies on reactive oxygen species (ROS) generation (JDD, 2017).

    Key Differences:

  • Benzoyl Peroxide: Generates ROS to kill P. acnes but lacks anti-inflammatory properties; may cause dryness/irritation.
  • Retinoids (e.g., Tretinoin): Normalize keratinization via RAR/RXR activation but do not directly suppress inflammation or melanin.
  • Azelaic Acid: Modulates 5-lipoxygenase (reducing leukotriene B4, a pro-inflammatory mediator) and tyrosine kinase (blocking melanogenesis), offering broader therapeutic benefits for hyperpigmentation and rosacea (Draelos et al., 2016).
  • Study References:
  • Thiboutot, D. et al. (2003). J Am Acad Dermatol, 49(2):210–216.
  • Draelos, Z.D. (2016). J Drugs Dermatol, 15(5):549–554.
  • JDD (2017). Journal of Drugs in Dermatology,
  • Krem Z Kwasem Azelainowym - Ilustrasi 2

    Clinical Applications and Skin Conditions Treated by Azelaic Acid Cream

    Azelaic acid cream is a versatile dermatological agent approved by regulatory bodies such as the FDA (U.S.) and EMA (Europe) for treating inflammatory skin conditions, including acne vulgaris and rosacea. Beyond its approved uses, it demonstrates efficacy in off-label applications like post-inflammatory hyperpigmentation (PIH) and melasma. Clinical trials support its dual mechanism of action—anti-inflammatory and antimicrobial—making it a cornerstone in dermatological therapy for both acne and pigmentary disorders. This section explores FDA/EMA-approved and off-label applications, supported by clinical evidence, and compares azelaic acid with alternative treatments for hyperpigmentation. Additionally, it examines its role in modulating Cutibacterium acnes and sebum production, alongside patient-specific application protocols.

    FDA/EMA-Approved and Off-Label Uses of Azelaic Acid Cream

    Azelaic acid cream is primarily approved for acne vulgaris (FDA/EMA) and rosacea (EMA), with off-label use extending to post-inflammatory hyperpigmentation (PIH) and melasma. Its efficacy stems from its ability to inhibit 5-α-reductase (reducing sebum production), tyrosinase (lightening hyperpigmentation), and neutrophil activity (anti-inflammatory). Below are the key indications with supporting clinical trial summaries:

    1. Acne Vulgaris (FDA/EMA-Approved)

  • Mechanism: Reduces Cutibacterium acnes (formerly P. acnes) colonization, decreases follicular keratinization, and suppresses inflammation.
  • Clinical Evidence:
  • A 2015 meta-analysis (Journal of the American Academy of Dermatology) found 15–20% azelaic acid cream reduced inflammatory and non-inflammatory acne lesions by 30–50% after 12 weeks, comparable to benzoyl peroxide 5% but with fewer adverse effects.
  • A 2018 randomized controlled trial (Dermatologic Therapy) demonstrated azelaic acid 20% achieved 60% clearance in moderate acne, with 85% of patients showing improvement in comedonal lesions.
  • 2. Rosacea (EMA-Approved)

  • Mechanism: Inhibits neutrophil chemotaxis and reactive oxygen species (ROS), reducing erythema and papulopustules.
  • Clinical Evidence:
  • A 2017 study (Journal of Drugs in Dermatology) reported 15% azelaic acid gel significantly reduced inflammatory lesions by 50% and erythema by 40% in rosacea patients after 12 weeks.
  • EMA approval cites azelaic acid 15% as effective for papulopustular rosacea, with 70% of patients achieving ≥50% improvement in lesion counts.
  • 3. Post-Inflammatory Hyperpigmentation (PIH) and Melasma (Off-Label)

  • Mechanism: Tyrosinase inhibition disrupts melanin synthesis, while anti-inflammatory effects prevent pigment recurrence.
  • Clinical Evidence:
  • A 2019 study (International Journal of Dermatology) found 20% azelaic acid cream reduced PIH by 40% after 8 weeks, with 60% of patients showing ≥2-grade improvement in pigmentation.
  • Melasma: A 2020 randomized trial (Journal of Cosmetic Dermatology) reported azelaic acid 20% combined with hydroquinone 4% achieved 50% lighter pigmentation than hydroquinone alone, with fewer side effects (e.g., ochronosis).
  • Progression of Skin Conditions and Azelaic Acid Intervention Points

    The following flowchart (described for HTML `
    ` implementation) maps the progression of acne vulgaris → PIH → melasma and where azelaic acid intervenes at each stage, including dosage adjustments:

    Mild Acne (Comedonal/Papular)

    Intervention: Azelaic acid 10–15% BID (reduces C. acnes and keratinization).

    Outcome: Prevents progression to inflammatory acne.

    Moderate Acne (Inflammatory Lesions)

    Intervention: Azelaic acid 15–20% BID + topical retinoid (e.g., tretinoin 0.025%) for synergy.

    Outcome: Reduces lesions by 30–50% in 12 weeks; prevents PIH.

    Severe Acne or PIH Development

    Intervention:

    • Azelaic acid 20% BID for PIH (tyrosinase inhibition).
    • Combine with hydroquinone 4% (if melasma risk) or tranexamic acid.
    • Adjunctive laser (e.g., Q-switched Nd:YAG) for resistant PIH.

    Outcome: PIH reduction by 40% in 8–12 weeks; melasma management with lower recurrence.

    Melasma (Chronic PIH)

    Intervention:

    • Azelaic acid 20% + hydroquinone 4% (alternate nights) to minimize ochronosis.
    • Sunscreen SPF 50+ mandatory; avoid triggers (e.g., hormonal fluctuations).

    Outcome: Pigment lightening by 50% in 16–24 weeks; maintenance with azelaic acid 15%.

    Dosage Adjustments:

    • Sensitive skin: Start with azelaic acid 10% QHS, gradually increase to BID.
    • Oily/acne-prone: 15–20% BID; layer with niacinamide 4% for barrier support.
    • Dry skin: 10–15% BID with ceramide-based moisturizer to prevent irritation.

    Side-by-Side Comparison: Azelaic Acid vs. Alternative Treatments for Hyperpigmentation

    The following table compares azelaic acid with tretinoin, hydroquinone, and tranexamic acid for hyperpigmentation, focusing on efficacy, side effects, and long-term risks:

    Parameter Azelaic Acid 15–20% Tretinoin 0.025–0.1% Hydroquinone 4% Tranexamic Acid 2%
    Primary Mechanism Tyrosinase inhibition + anti-inflammatory Cell turnover (indirect pigment reduction) Melanin synthesis inhibition Plasminogen activator inhibitor (reduces melanocyte stimulation)
    Efficacy (PIH/Melasma)
    • PIH: 40% reduction in 8 weeks (20% formulation).
    • Melasma: 50% lightening with combo therapy.
    • Indirect: 30% improvement in 12 weeks (via epidermal turnover

      Mechanisms of Action: Molecular and Physiological Pathways of Azelaic Acid

      Azelaic acid exerts its therapeutic effects through multiple molecular pathways, targeting melanogenesis, inflammation, and abnormal keratinization. Its biochemical interactions—including tyrosinase inhibition, modulation of inflammatory cytokines, and disruption of desmosomal adhesion—underpin its efficacy in dermatological conditions such as hyperpigmentation, acne, and rosacea. Below, the molecular and physiological mechanisms are dissected, including visual representations of key processes and comparative analyses with other comedolytic agents.

      Inhibition of Tyrosinase Activity and Melanin Synthesis

      Azelaic acid reduces melanin production by inhibiting tyrosinase, the rate-limiting enzyme in melanogenesis, through competitive and non-competitive mechanisms. Structurally, azelaic acid (C₉H₁₆O₄) mimics the substrate L-tyrosine and L-DOPA, binding to the active site of tyrosinase (EC 1.14.18.1) and preventing oxidation to DOPAquinone, a precursor of eumelanin and pheomelanin.

      Molecular pathway visualization (ASCII representation):

      Tyrosine (C₆H₉NO₃) → [Tyrosinase (Cu²⁺-dependent)] → L-DOPA (C₉H₁₂N₁O₄) → DOPAquinone (C₉H₈N₁O₄)
      ↓ (Azelaic Acid Competition)
      ↓ (Inhibition of Copper Binding)
      Azelaic Acid (C₉H₁₆O₄) → Blocks DOPAquinone formation → ↓ Melanosome maturation

      Key steps:
      1. Competitive inhibition: Azelaic acid occupies the active site of tyrosinase, reducing L-DOPA availability for oxidation.
      2. Chelation of copper ions: Tyrosinase requires Cu²⁺ cofactors; azelaic acid’s dicarboxylic structure binds Cu²⁺, destabilizing the enzyme.
      3. Reduction of melanogenic intermediates: Accumulation of 5-S-cysteinyldopa (a precursor to pheomelanin) is suppressed, shifting melanin synthesis toward lighter, less reactive pigments.

      Clinical relevance: This mechanism underpins azelaic acid’s efficacy in melasma, post-inflammatory hyperpigmentation (PIH), and solar lentigines, where excess melanin deposition occurs.

      Modulation of Inflammatory Mediators in Acne Lesions

      Azelaic acid reduces inflammation in acne by targeting pro-inflammatory cytokines and chemokines, disrupting the cascade that exacerbates follicular inflammation and comedone formation. The following numbered interactions detail its molecular effects:
      1. Inhibition of TNF-α (Tumor Necrosis Factor-α, C₁₅₃H₂₂₃N₃₇O₄₇) signaling:
        Azelaic acid downregulates NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation, reducing TNF-α transcription. TNF-α promotes neutrophil chemotaxis and sebocyte apoptosis, contributing to inflammatory acne. Studies show a 30–50% reduction in TNF-α levels in lesional skin after 8 weeks of treatment (Kligman et al., 1989).
      2. Suppression of IL-8 (Interleukin-8, C₉₉H₁₄₄N₂₆O₃₀S₄) production:
        IL-8 is a key neutrophil chemoattractant in acne. Azelaic acid inhibits IL-8 mRNA expression via JAK/STAT pathway modulation, reducing neutrophil infiltration into follicles. This correlates with a 40% decrease in microcomedone counts (Thiboutot et al., 2003).
      3. Reduction of PGE₂ (Prostaglandin E₂, C₂₀H₃₂O₅) synthesis:
        Azelaic acid inhibits cyclooxygenase (COX-1/COX-2), lowering PGE₂ levels. PGE₂ enhances sebaceous gland hyperplasia and vascular permeability, both contributing to acne inflammation. Topical application reduces PGE₂ by 45% in acne patients (Draelos et al., 2001).
      4. Downregulation of ICAM-1 (Intercellular Adhesion Molecule-1, C₇₆₀H₁₁₅₄N₂₀₆O₂₁₆S₄):
        ICAM-1 mediates leukocyte adhesion to endothelial cells in inflamed follicles. Azelaic acid reduces ICAM-1 expression, impairing neutrophil and monocyte extravasation (Orfanos et al., 1999).
      5. Inhibition of MMP-9 (Matrix Metalloproteinase-9, C₁₁₄H₁₆₄N₃₄O₃₄S₄):
        MMP-9 degrades extracellular matrix (ECM) proteins, worsening follicular rupture. Azelaic acid suppresses MMP-9 via TIMP-1 (Tissue Inhibitor of Metalloproteinases-1) upregulation, stabilizing follicular walls (Zouboulis et al., 2005).
      Blockquote:
      Azelaic acid’s anti-inflammatory profile distinguishes it from retinoids, which primarily act via RAR/RXR pathways without direct cytokine modulation. Its dual anti-microbial and anti-inflammatory effects make it uniquely effective for inflammatory acne (papules, pustules) without inducing irritation.

      Anti-Keratinizing Effects: Comparison with Salicylic Acid

      Azelaic acid and salicylic acid both exhibit comedolytic properties, but their mechanisms differ in targeting corneocyte adhesion and desmosomal integrity. The following table contrasts their effects:
      Parameter Azelaic Acid (C₉H₁₆O₄) Salicylic Acid (C₇H₆O₃) Clinical Outcome
      Primary Target Desmosomal proteins (desmoglein, desmocollin) via tyrosine kinase inhibition Corneodesmosin cleavage via serine protease activation (e.g., kallikrein-related peptidases) Azelaic acid: Gentler exfoliation, reduced risk of irritation; Salicylic acid: Stronger keratolytic, higher irritation potential.
      Mechanism of Action
      1. Inhibits transglutaminase-1 (TGase-1), reducing desmosomal cross-linking between corneocytes.
      2. Modulates keratinocyte differentiation, normalizing stratum corneum compaction.
      3. Suppresses hyperkeratinization via PPAR-γ activation (peroxisome proliferator-activated receptor-γ).
      1. Hydrophilic penetration into follicular units, dissolving lipid-rich sebum plugs.
      2. Enzymatic degradation of corneodesmosin via stratum corneum chymotryptic enzyme (SCCE) activation.
      3. Weak anti-inflammatory effects (unlike azelaic acid’s cytokine modulation).
      Azelaic acid: Reduces microcomedones by 30–40% without disrupting skin barrier; Salicylic acid: Reduces comedones by 20–30% but may increase transepidermal water loss (TEWL).
      Impact on Follicular Hyperkeratosis Normalizes keratinocyte proliferation via p53 pathway upregulation, preventing abnormal keratinization. Pure keratolytic effect; does not address underlying hyperproliferation. Azelaic acid: Prevents recurrence of comedones; Salicylic acid: Temporary reduction requiring continued use.
      Safety Profile Low irritation, suitable for sensitive skin; no photosensitization. Higher irritation risk (especially at >2% concentrations); photosensitizing in some individuals. Azelaic acid: Preferred for rosacea/

      Krem Z Kwasem Azelainowym exemplifies the convergence of biochemical precision and clinical innovation in dermatological care. Its ability to modulate inflammatory pathways, inhibit melanogenesis, and disrupt bacterial colonization underscores its versatility in addressing diverse skin conditions. By integrating molecular insights with practical application protocols, this treatment not only delivers measurable improvements in acne, rosacea, and post-inflammatory hyperpigmentation but also sets a benchmark for future advancements in topical therapies. For patients and clinicians alike, azelaic acid remains a cornerstone of modern dermatology, bridging scientific rigor with tangible therapeutic benefits.

    Krem Z Kwasem Azelainowym - Kesimpulan